EDEN PRAIRIE, Minn., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Critically-ill children and babies with kidney failure or who are dependent on artificial kidney support currently do not have enough therapeutic options. Nuwellis (NASDAQ:NUWE) plans to fill this unmet need with the development of a fully integrated pediatric continuous renal replacement therapy (CRRT) device designed to provide care for small babies and children. Nuwellis is a medical device company dedicated to transforming care for patients suffering from fluid imbalance. The new device will build on the existing technology of the company's Aquadex SmartFlow® system, and will be funded in part by a $1.7 million grant from the Nati

EDEN PRAIRIE, Minn., July 27, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), announced today that its second quarter 2021 financial results will be released on Tuesday, August 10, 2021. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company's financial results and provide a general business overview. To access the live webcast, please visit the Investors page of the Nuwellis website at http://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing (877) 303-9826 (U.S.) or (224) 357-2194 (international) and using conference ID: 1396749. An audio archive of the webcast will be available following

EDEN PRAIRIE, Minn., July 13, 2021 (GLOBE NEWSWIRE) -- In an effort to increase the availability of life-saving ultrafiltration therapy to people experiencing fluid overload, the American Medical Association (AMA) has issued a new Category III Current Procedural Terminology (CPT®) code, 0692T for Therapeutic Ultrafiltration. The new CPT code will come into effect on January 1, 2022, at which time providers can utilize the code when using Aquadex® to deliver ultrafiltration to adults and children (20 kg or more). Aquadex is developed and marketed by Nuwellis, Inc. (NASDAQ:NUWE). A specific code for ultrafiltration was granted after a thorough review and validation that the technology met t

EDEN PRAIRIE, Minn., June 22, 2021 (GLOBE NEWSWIRE) -- Continuing its dynamic growth in support of its commitment to expanding access to life-saving ultrafiltration therapies for adult and pediatric patients suffering from fluid overload, Nuwellis, Inc. (NASDAQ:NUWE), formerly CHF Solutions, Inc., today announced the appointment of George Montague as Chief Financial Officer, effective June 28, 2021. Neil P. Ayotte, Esq. also joined the Company as Senior Vice President, General Counsel, Secretary and Chief Compliance Officer on June 7, 2021. "Nuwellis is entering an energizing new phase with significant opportunities in heart failure, pediatrics and critical care. The deep knowledge and ex

EDEN PRAIRIE, Minn., June 01, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), formerly CHF Solutions, Inc., has been awarded a three-year national contract with Premier, Inc., effective today. The new Aquapheresis category agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Aquadex SmartFlow®, the gentle fluid management technology developed by Nuwellis.       Aquadex® is the first and only therapy currently available in this newly-established Aquapheresis product category. The collaboration provides Nuwellis with the opportunity to expand into many of the thousands of hospitals with which Premier holds

EDEN PRAIRIE, Minn., May 17, 2021 (GLOBE NEWSWIRE) -- Data supporting the effectiveness of Aquadex FlexFlow® system in the treatment of acutely decompensated heart failure (ADHF) patients was presented May 16th at the 2021 American College of Cardiology conference (ACC). The single-center study evaluated 30 ADHF patients in mainstream setting (i.e., step-down unit, not critical care) who were treated with Aquadex therapy. The Aquadex FlexFlow is developed by Nuwellis, Inc. (NASDAQ:NUWE), formerly CHF Solutions, Inc., a company dedicated to changing the lives of people suffering from fluid overload. The study showed 83% of patients treated with Aquadex therapy experienced clinical sympto

EDEN PRAIRIE, Minn., May 11, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE) (previously CHF Solutions, Inc.) announced today its results for the first quarter ended March 31, 2021, which included the following highlights: Completed corporate rebranding from CHF Solutions, Inc. to Nuwellis, Inc. on April 27, 2021Revenue for the first quarter ended March 31, 2021, was $1.9 million, an increase of 18 percent compared to the prior year periodIncreased Aquadex therapy utilization amongst strategic Critical Care accounts; highest levels seen in the past five quartersEnrolled first pediatric patient into clinical registry in April 2021Received strong endorsements f

EDEN PRAIRIE, Minn., April 29, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), formally CHF Solutions, announces today that its first quarter 2021 financial results will be released on Tuesday, May 11, 2021. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company's financial results and provide a general business overview. To access the live webcast, please visit the Investors page of the Nuwellis website at http://ir.nuwellis.com or access the webcast directly at http://ir.nuwellis.com/events. Alternatively, you may access the live conference call by dialing (877) 303-9826 (U.S.) or (224) 357-2194 (international) and usin

EDEN PRAIRIE, Minn., April 27, 2021 (GLOBE NEWSWIRE) -- Company names are reflective of the services provided to its customers, and CHF Solutions – a leader and pioneer in the heart failure space – has evolved to serve more than just the chronic heart failure community. The company today announced it is now Nuwellis, Inc. (NASDAQ:NUWE) to reflect its core therapeutic focus areas: pediatric, critical care, and heart failure fluid imbalance. Historically, the company's Aquadex SmartFlow® System was used to remove excess fluid in patients suffering from heart failure, helping to alleviate the burden that fluid overload has on vital organs and subsequently reducing the need for hospital

EDEN PRAIRIE, Minn., April 23, 2021 (GLOBE NEWSWIRE) -- Improving access to life-saving fluid management therapies is a commitment CHF Solutions (NASDAQ:CHFS) stands by. The company today announced Aquadex SmartFlow® is now available at two new pediatric hospitals in Texas. CHF Solutions is a medical device company dedicated to changing the lives of patients suffering from fluid overload. Pediatric patients suffering from fluid overload require gentle treatment approaches, which makes Aquadex® uniquely beneficial for children. The device is designed to remove small amounts of fluid over time and only requires 35 ml of extracorporeal fluid. This is a key differentiator compared to other fl

SC 13G - CHF Solutions, Inc. (0001506492) (Subject)

SC 13G - CHF Solutions, Inc. (0001506492) (Subject)

SC 13G/A - CHF Solutions, Inc. (0001506492) (Subject)

SC 13G/A - CHF Solutions, Inc. (0001506492) (Subject)

EDEN PRAIRIE, Minn., June 22, 2021 (GLOBE NEWSWIRE) -- Continuing its dynamic growth in support of its commitment to expanding access to life-saving ultrafiltration therapies for adult and pediatric patients suffering from fluid overload, Nuwellis, Inc. (NASDAQ:NUWE), formerly CHF Solutions, Inc., today announced the appointment of George Montague as Chief Financial Officer, effective June 28, 2021. Neil P. Ayotte, Esq. also joined the Company as Senior Vice President, General Counsel, Secretary and Chief Compliance Officer on June 7, 2021. "Nuwellis is entering an energizing new phase with significant opportunities in heart failure, pediatrics and critical care. The deep knowledge and ex

EDEN PRAIRIE, Minn., Jan. 19, 2021 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced the appointment of President and Chief Operating Officer Nestor Jaramillo, Jr. to President and Chief Executive Officer (CEO), effective immediately. Predecessor CEO John Erb will continue to serve as the company’s Chairman of the Board. Mr. Jaramillo joined CHF Solutions in May 2019 and has driven the evolution of the company’s therapeutic focus strategy from solely heart failure to an expansion into critical care and pediatrics. His vision to transform the trajectory of cardiorenal disea

3 - CHF Solutions, Inc. (0001506492) (Issuer)

4 - CHF Solutions, Inc. (0001506492) (Issuer)

4 - CHF Solutions, Inc. (0001506492) (Issuer)

4 - CHF Solutions, Inc. (0001506492) (Issuer)

4 - CHF Solutions, Inc. (0001506492) (Issuer)

8-K - Nuwellis, Inc. (0001506492) (Filer)

DEF 14A - CHF Solutions, Inc. (0001506492) (Filer)

8-K - CHF Solutions, Inc. (0001506492) (Filer)

10-K - CHF Solutions, Inc. (0001506492) (Filer)

424B5 - CHF Solutions, Inc. (0001506492) (Filer)

8-K - CHF Solutions, Inc. (0001506492) (Filer)

S-3MEF - CHF Solutions, Inc. (0001506492) (Filer)

424B5 - CHF Solutions, Inc. (0001506492) (Filer)

8-K - CHF Solutions, Inc. (0001506492) (Filer)

8-K/A - CHF Solutions, Inc. (0001506492) (Filer)